Molybdenum cofactor deficiency (MoCD) type A is a very rare, autosomal recessive hereditary metabolic disorder that usually begins neonatally. It is caused by biallelic variants in MOCS1, which block the first step of molybdenum cofactor synthesis. As a consequence, several cofactor-dependent enzymes fail, especially sulfite oxidase, with the accumulation of toxic metabolites and severe neurological damage.
Molybdenum cofactor deficiency type A
The MOCS1 gene encodes proteins necessary to form the initial precursor of the molybdenum cofactor, cPMP. This cofactor is an essential auxiliary molecule for the activity of enzymes such as sulfite oxidase, xanthine oxidoreductase, and aldehyde oxidase. Without functional Moco, these enzymes cannot complete key detoxification and metabolism reactions.
MoCD type A deficiency appears when pathogenic variants in MOCS1 prevent the production of cPMP. The main consequence is the loss of sulfite oxidase activity, with the accumulation of sulfite, S-sulfocysteine, and other neurotoxic compounds. This toxicity preferentially affects the central nervous system and explains seizures, encephalopathy, and early neurological deterioration. The disease is inherited in an autosomal recessive manner, so an affected person must inherit two altered copies of the gene, one from each parent. It is an ultra-rare condition, with an estimated incidence close to 1 in 100,000-200,000 live births, likely underdiagnosed due to its severity and initial similarity to hypoxic-ischemic encephalopathy.
Symptoms
The onset usually occurs in the first few days of life. Newborns may present feeding difficulties, inconsolable crying, axial hypotonia, increased tone in the limbs, refractory seizures, and progressive encephalopathy. The clinical picture can be confused with hypoxia or perinatal asphyxia. Without early treatment, brain damage progresses rapidly and can lead to severe developmental delay, acquired microcephaly, visual impairments, and death in early childhood. The prognosis depends largely on how quickly specific treatment is initiated.
Disease management
Management should be initiated urgently upon clinical or biochemical suspicion. For MoCD type A deficiency, there is specific treatment with fosdenopterin (Nulibry), a cPMP replacement that allows for the continued synthesis of the molybdenum cofactor; its benefit is greater when administered very early, before neurological damage becomes irreversible. In addition, seizure control, nutritional and respiratory support when necessary, neurological and metabolic monitoring, and individualized measures to reduce the burden of sulfur compounds are required.
Genes analyzed
Bibliography
Kumar A, Dejanovic B, Hetsch F, et al. S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency. J Clin Invest. 2017 Dec 1;127(12):4365-4378.
Misko AL, Liang Y, Kohl JB, et al. Delineating the phenotypic spectrum of sulfite oxidase and molybdenum cofactor deficiency. Neurol Genet. 2020 Jul 14;6(4):e486.
Stence NV, Coughlin CR 2nd, Fenton LZ, et al. Distinctive pattern of restricted diffusion in a neonate with molybdenum cofactor deficiency. Pediatr Radiol. 2013 Jul;43(7):882-5.
Macaya A, Brunso L, Fernández-Castillo N, et al. Molybdenum cofactor deficiency presenting as neonatal hyperekplexia: a clinical, biochemical and genetic study. Neuropediatrics. 2005 Dec;36(6):389-94.
